HMGB1 and Hypoalbuminemia: There are individual parameters that have been associated with a higher risk of resistance, such as age under 12 months, hypoalbuminemia, transaminasemia, and neutrophilic leukocytosis, as well as genetic factors such as single nucleotide polymorphisms (SNPs) in IFN-γ, DC-SIGN, IL-1B, MRP4, BAZ1A, STX1B, high mobility group box 1 (HMGB1), and P2Y12 (P2RY12) genes, whose children require more aggressive therapies with monoclonal antibodies and immunomodulators [35].